Further analysis of the VAF showed a significantly higher percentage of VAF for ARID1A and TP53 mutations in patients with r/r MB-NHLs than in patients with IR MB-NHL (TP53 VAF: IR MB-NHL: median = 20.33%, IQR: 0-47.4%, r/r MB-NHL: median = 53.1%, IQR: 0-83.8%, P = 0.0075; ARID1A VAF: IR MB-NHL: median = 0%, IQR: 0–0%, r/r MB-NHL: median = 0%, IQR: 0-43.4%, P = 0.0025). Here, ARID1A is linked to non-Hodgkin lymphoma.